QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.084186v1 314/2/603    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoagland, M. S. Articles by Swanson, H. I. Search for Related Content PubMed PubMed Citation Articles by Hoagland, M. S. Articles by Swanson, H. I.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

The p53 Inhibitor Pifithrin- Is a Potent Agonist of the Aryl Hydrocarbon Receptor

Department of Molecular and Biomedical Pharmacology, University of Kentucky Medical Center, Lexington, Kentucky

The tumor suppressor protein p53 is currently a target of emerging drug therapies directed toward neurodegenerative diseases, such as Alzheimer's and Parkinson's, and side effects associated with cancer treatments. Of this group of drugs, the best characterized is pifithrin-, a small molecule that inhibits p53-dependent apoptosis through an undetermined mechanism. In this study, we have used a number of molecular approaches to test the hypothesis that pifithrin- acts as an aryl hydrocarbon receptor (AhR) agonist and, in this manner, inhibits the actions of p53. Toward this end, we have found that pifithrin- is a potent AhR agonist as determined by its ability to bind the AhR, induce formation of its DNA binding complex, activate reporter activity, and up-regulate the classic AhR target gene CYP1A1. However, examination of its ability to inhibit p53-mediated gene activation and apoptosis revealed that these actions occurred via an AhR-independent manner. The significance of this study is based on the fact that activation of the AhR is typically associated with an increase in phase I and phase II metabolizing enzymes and adverse biological events such as tumor promotion that may contribute to untoward effects of pifithrin-. Hence, this work will aid in the future design of more specific members of this important class of p53 inhibitors for use in a clinical setting.

Address correspondence to: Dr. Hollie I. Swanson, UKMC MS-305, 800 Rose St., Lexington, KY 40536-0084. E-mail: hswan{at}uky.edu

This article has been cited by other articles:

				N. Ishimaru, A. Takagi, M. Kohashi, A. Yamada, R. Arakaki, J. Kanno, and Y. Hayashi Neonatal Exposure to Low-Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin Causes Autoimmunity Due to the Disruption of T Cell Tolerance J. Immunol., May 15, 2009; 182(10): 6576 - 6586. [Abstract] [Full Text] [PDF]

				J.-M. SU, P. LIN, C.-K. WANG, and H. CHANG Overexpression of Cytochrome P450 1B1 in Advanced Non-small Cell Lung Cancer: A Potential Therapeutic Target Anticancer Res, February 1, 2009; 29(2): 509 - 515. [Abstract] [Full Text] [PDF]

				A. C. Grimes, K. N. Erwin, H. A. Stadt, G. L. Hunter, H. A. Gefroh, H.-J. Tsai, and M. L. Kirby PCB126 Exposure Disrupts ZebraFish Ventricular and Branchial but Not Early Neural Crest Development Toxicol. Sci., November 1, 2008; 106(1): 193 - 205. [Abstract] [Full Text] [PDF]

				D. Puppala, H. Lee, K. B. Kim, and H. I. Swanson Development of an Aryl Hydrocarbon Receptor Antagonist Using the Proteolysis-Targeting Chimeric Molecules Approach: A Potential Tool for Chemoprevention Mol. Pharmacol., April 1, 2008; 73(4): 1064 - 1071. [Abstract] [Full Text] [PDF]

				D. Puppala, C.G. Gairola, and H.I. Swanson Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation Carcinogenesis, March 1, 2007; 28(3): 639 - 647. [Abstract] [Full Text] [PDF]

				R. Wu, L. Zhang, M. S. Hoagland, and H. I. Swanson Lack of the Aryl Hydrocarbon Receptor Leads to Impaired Activation of AKT/Protein Kinase B and Enhanced Sensitivity to Apoptosis Induced via the Intrinsic Pathway J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 448 - 457. [Abstract] [Full Text] [PDF]

				H. Wehbe, R. Henson, M. Lang, F. Meng, and T. Patel Pifithrin-{alpha} Enhances Chemosensitivity by a p38 Mitogen-Activated Protein Kinase-Dependent Modulation of the Eukaryotic Initiation Factor 4E in Malignant Cholangiocytes J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1153 - 1161. [Abstract] [Full Text] [PDF]

				L. Sparfel, J. Van Grevenynghe, M. Le Vee, C. Aninat, and O. Fardel Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin {alpha} Carcinogenesis, March 1, 2006; 27(3): 656 - 663. [Abstract] [Full Text] [PDF]